Jacobio Boosts Share Buybacks and Liquidity as Oncology Pipeline Advances

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks An announcement from Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ) is now available. Jacobio Pharmaceuticals has been steadily repurchasing its own shares under an existing mandate, accumulating 7,47,800 treasury shares at a total cost of about HK$34.17 million. The board argues that the current share price undervalues the company’s core oncology pipeline and commercialization potential, and signals continued confidence by reserving the option to conduct further buybacks depending on market conditions. The company’s liquidity has been bolstered by a US$100 million upfront payment from its strategic collaboration with AstraZeneca and RMB8.55 million in royalties from Allist, bringing its cash, capital‑protected deposits and available bank credit to roughly RMB2.1 billion. Management estimates this cash runway will last at least four years, supporting ongoing development of its oncology portfolio and global expansion, which in turn underpins its long‑term strategy and commitment to enhancing shareholder value. The most recent analyst rating on (HK:1167) stock is a Buy with a HK$10.34 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page. More about Jacobio Pharmaceuticals Group Co., Ltd. Jacobio Pharmaceuticals Group is a Cayman Islands–incorporated biotechnology company focused on developing innovative oncology therapies. The group concentrates on core oncology drug pipelines with a view to commercialization and global business expansion, positioning itself within the cancer treatment segment of the pharmaceutical industry. Average Trading Volume: 3,166,367 Technical Sentiment Signal: Sell Current Market Cap: HK$4.53B